Shockwave Medical (NASDAQ:SWAV) Announces Quarterly Earnings Results
Shockwave Medical (NASDAQ:SWAV) released its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.02, Bloomberg Earnings reports. The firm had revenue of $14.31 million during the quarter, compared to analysts’ expectations of $13.34 million. Shockwave Medical updated its FY 2020
After-Hours guidance to EPS.
Shares of SWAV traded down $3.39 during trading hours on Friday, reaching $44.35. 1,393,600 shares of the company traded hands, compared to its average volume of 379,907. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.76 and a quick ratio of 6.28. Shockwave Medical has a 12-month low of $24.58 and a 12-month high of $68.39. The business has a fifty day moving average price of $44.17 and a 200-day moving average price of $39.31.
In other news, major shareholder Sofinnova Capital Vii Fcpr sold 169,450 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $43.99, for a total transaction of $7,454,105.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Isaac Zacharias sold 4,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $40.24, for a total transaction of $160,960.00. Following the sale, the insider now directly owns 9,000 shares in the company, valued at $362,160. The disclosure for this sale can be found here. Insiders have sold 542,000 shares of company stock worth $23,600,976 over the last three months.
Shockwave Medical Company Profile
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Featured Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.